Management of severe pneumonia in respiratory non-intensive care unit: a retrospective study from a single center experience.

IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Frontiers in Medicine Pub Date : 2025-09-18 eCollection Date: 2025-01-01 DOI:10.3389/fmed.2025.1666800
Lucrezia Pisanu, Marianna Russo, Maria Arminio, Lorenzo Arlando, Valentina Conio, Francesco Rocco Bertuccio, Klodjana Mucaj, Mitela Tafa, Giulia Maria Stella, Angelo Guido Corsico
{"title":"Management of severe pneumonia in respiratory non-intensive care unit: a retrospective study from a single center experience.","authors":"Lucrezia Pisanu, Marianna Russo, Maria Arminio, Lorenzo Arlando, Valentina Conio, Francesco Rocco Bertuccio, Klodjana Mucaj, Mitela Tafa, Giulia Maria Stella, Angelo Guido Corsico","doi":"10.3389/fmed.2025.1666800","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Severe pneumonia management in the hospital setting often relies heavily on established clinical practice and physician experience. This approach has the purpose of enabling early identification of risk factors most strongly associated with severe pneumonia at the time of hospital admission.</p><p><strong>Methods: </strong>This retrospective study analyzed inpatients with pneumonia treated in a Respiratory disease unit, stratifying them into two groups-severe and non-severe pneumonia - according to the 2007 IDSA/ATS criteria, identifying differences in demographic profiles, clinical features, treatment strategies, and prognostic outcomes.</p><p><strong>Results: </strong>Out of a cohort of 302 patients, 26 (8.6%) met the criteria for severe pneumonia. A statistically significant difference was observed in the Pneumonia Severity Index (PSI > 90), recorded in 61.53% of patients with severe pneumonia compared to 41.31% in non-severe cases. The Charlson Comorbidity Index (CCI ≥ 4), indicative of lower 10-year survival due to comorbidities, was significantly more frequent in the severe group (84.61% vs. 61.23%). Microbiological analysis of bronchoalveolar lavage (BAL) showed a positivity rate of 75% in the severe group versus 35.48% in the non-severe group (<i>p</i> < 0.05). Significant differences were also found in the use of respiratory support: high-flow nasal cannula (HFNC) was used in 69.23% of severe cases versus 32.97% in non-severe cases, while CPAP was administered in 23.07% versus 5.43%, respectively. Finally, antibiotic therapy was significantly longer in the severe group, with a mean duration of 14.69 days compared to 11.77 days in non-severe patients, involving both intravenous and oral regimens as part of initial or sequential treatment.</p><p><strong>Conclusion: </strong>Timely recognition of these factors is essential to ensure optimal patient care, facilitate close monitoring of critically ill individuals, allow for prompt therapeutic escalation, and support ICU admission when needed. This analysis highlights the need for a critical reassessment of existing guidelines and underscores the value of integrating them with real-world clinical experience.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1666800"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12488406/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1666800","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: Severe pneumonia management in the hospital setting often relies heavily on established clinical practice and physician experience. This approach has the purpose of enabling early identification of risk factors most strongly associated with severe pneumonia at the time of hospital admission.

Methods: This retrospective study analyzed inpatients with pneumonia treated in a Respiratory disease unit, stratifying them into two groups-severe and non-severe pneumonia - according to the 2007 IDSA/ATS criteria, identifying differences in demographic profiles, clinical features, treatment strategies, and prognostic outcomes.

Results: Out of a cohort of 302 patients, 26 (8.6%) met the criteria for severe pneumonia. A statistically significant difference was observed in the Pneumonia Severity Index (PSI > 90), recorded in 61.53% of patients with severe pneumonia compared to 41.31% in non-severe cases. The Charlson Comorbidity Index (CCI ≥ 4), indicative of lower 10-year survival due to comorbidities, was significantly more frequent in the severe group (84.61% vs. 61.23%). Microbiological analysis of bronchoalveolar lavage (BAL) showed a positivity rate of 75% in the severe group versus 35.48% in the non-severe group (p < 0.05). Significant differences were also found in the use of respiratory support: high-flow nasal cannula (HFNC) was used in 69.23% of severe cases versus 32.97% in non-severe cases, while CPAP was administered in 23.07% versus 5.43%, respectively. Finally, antibiotic therapy was significantly longer in the severe group, with a mean duration of 14.69 days compared to 11.77 days in non-severe patients, involving both intravenous and oral regimens as part of initial or sequential treatment.

Conclusion: Timely recognition of these factors is essential to ensure optimal patient care, facilitate close monitoring of critically ill individuals, allow for prompt therapeutic escalation, and support ICU admission when needed. This analysis highlights the need for a critical reassessment of existing guidelines and underscores the value of integrating them with real-world clinical experience.

非重症监护病房重症肺炎的管理:单中心回顾性研究
目的:重症肺炎的医院管理往往很大程度上依赖于既定的临床实践和医生的经验。这种方法的目的是能够在住院时及早发现与严重肺炎最密切相关的危险因素。方法:本回顾性研究分析了在呼吸疾病病房治疗的肺炎住院患者,根据2007年IDSA/ATS标准将其分为两组——重症和非重症肺炎,确定人口统计学特征、临床特征、治疗策略和预后结果的差异。结果:在302例患者中,26例(8.6%)符合重症肺炎标准。肺炎严重程度指数(PSI bbb90)差异有统计学意义,重症肺炎患者为61.53%,非重症肺炎患者为41.31%。Charlson共病指数(CCI≥4)在严重组中更为常见(84.61%比61.23%),表明共病导致的10年生存率较低。支气管肺泡灌洗(BAL)微生物学分析显示,重症组阳性率为75%,非重症组阳性率为35.48% (p < 0.05)。在呼吸支持的使用方面也存在显著差异:重症病例使用高流量鼻插管(HFNC)的比例为69.23%,非重症病例为32.97%,而使用CPAP的比例分别为23.07%和5.43%。最后,重症组的抗生素治疗时间明显更长,平均持续时间为14.69天,而非重症组的平均持续时间为11.77天,包括静脉注射和口服方案,作为初始或序贯治疗的一部分。结论:及时认识到这些因素对于确保最佳的患者护理,促进对危重患者的密切监测,允许及时的治疗升级,并在需要时支持ICU住院至关重要。该分析强调了对现有指南进行批判性重新评估的必要性,并强调了将其与实际临床经验相结合的价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Medicine
Frontiers in Medicine Medicine-General Medicine
CiteScore
5.10
自引率
5.10%
发文量
3710
审稿时长
12 weeks
期刊介绍: Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate - the use of patient-reported outcomes under real world conditions - the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines - the scientific bases for guidelines and decisions from regulatory authorities - access to medicinal products and medical devices worldwide - addressing the grand health challenges around the world
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信